168 related articles for article (PubMed ID: 22670158)
1. FDG PET/CT Response Evaluation in Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Chemotherapy.
Genestreti G; Moretti A; Piciucchi S; Giovannini N; Galassi R; Scarpi E; Burgio MA; Amadori D; Sanna S; Poletti V; Matteucci F; Gavelli G
J Cancer; 2012; 3():241-5. PubMed ID: 22670158
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive role of [
Zucali PA; Lopci E; Ceresoli GL; Giordano L; Perrino M; Ciocia G; Gianoncelli L; Lorenzi E; Simonelli M; De Vincenzo F; Setti LR; Bonifacio C; Bonomi M; Bombardieri E; Chiti A; Santoro A
Cancer Med; 2017 Oct; 6(10):2287-2296. PubMed ID: 28941158
[TBL] [Abstract][Full Text] [Related]
3. Histology of the pleural rind at [
Soltermann A; Opitz I; Burger IA
Pathol Res Pract; 2021 Dec; 228():153660. PubMed ID: 34749212
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of F18 Fluorothymidine positron emission tomography for assessing the response of malignant pleural mesothelioma to chemotherapy - A prospective cohort study.
May IJ; Nowak AK; Francis RJ; Ebert MA; Dhaliwal SS
J Med Imaging Radiat Oncol; 2024 Feb; 68(1):57-66. PubMed ID: 37898984
[TBL] [Abstract][Full Text] [Related]
5. Fluorodeoxyglucose versus Choline Positron Emission Tomography/Computed Tomography Response Evaluation in Two Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Neoadjuvant Chemotherapy.
Kitajima K; Nakamichi T; Hasegawa S; Kuribayashi K; Yamakado K
Cureus; 2018 Nov; 10(11):e3654. PubMed ID: 30723653
[TBL] [Abstract][Full Text] [Related]
6. Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis.
Kwek BH; Aquino SL; Fischman AJ
Chest; 2004 Jun; 125(6):2356-60. PubMed ID: 15189963
[TBL] [Abstract][Full Text] [Related]
7. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
Schaefer NG; Veit-Haibach P; Soyka JD; Steinert HC; Stahel RA
Eur J Radiol; 2012 Jan; 81(1):e19-25. PubMed ID: 21129871
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma.
Genestreti G; Moretti A; Piciucchi S; Tiseo M; Bersanelli M; Scarlattei M; Scarpi E; Dubini A; Matteucci F; Sanna S
Technol Cancer Res Treat; 2012 Apr; 11(2):163-7. PubMed ID: 22335410
[TBL] [Abstract][Full Text] [Related]
9. Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma.
Pilling J; Dartnell JA; Lang-Lazdunski L
Thorac Cardiovasc Surg; 2010 Jun; 58(4):215-9. PubMed ID: 20514576
[TBL] [Abstract][Full Text] [Related]
10. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
Kanemura S; Kuribayashi K; Funaguchi N; Shibata E; Mikami K; Doi H; Kitajima K; Hasegawa S; Nakano T
Eur J Radiol; 2017 Jan; 86():92-98. PubMed ID: 28027772
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
Abe Y; Tamura K; Sakata I; Ishida J; Ozeki Y; Tamura A; Uematsu K; Sakai H; Goya T; Kanazawa M; Machida K
Oncol Rep; 2012 Feb; 27(2):333-8. PubMed ID: 22024889
[TBL] [Abstract][Full Text] [Related]
12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma.
Lopci E; Zucali PA; Ceresoli GL; Perrino M; Giordano L; Gianoncelli L; Lorenzi E; Gemelli M; Santoro A; Chiti A
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):667-75. PubMed ID: 25403555
[TBL] [Abstract][Full Text] [Related]
14. F-18 FDG PET/CT characterization of talc pleurodesis-induced pleural changes over time: a retrospective study.
Nguyen NC; Tran I; Hueser CN; Oliver D; Farghaly HR; Osman MM
Clin Nucl Med; 2009 Dec; 34(12):886-90. PubMed ID: 20139823
[TBL] [Abstract][Full Text] [Related]
15.
Niccoli Asabella A; Di Palo A; Altini C; Fanelli M; Ferrari C; Lavelli V; Ranieri G; Gadaleta CD; Rubini G
Hell J Nucl Med; 2018; 21(3):191-197. PubMed ID: 30411729
[TBL] [Abstract][Full Text] [Related]
16. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
Sharif S; Zahid I; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 May; 12(5):806-11. PubMed ID: 21266493
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of
Söyler Y; Özmen Ö; Kabalak PA; Ertürk H; Uğurman F; Yılmaz Ü
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(1):3-9. PubMed ID: 36152987
[TBL] [Abstract][Full Text] [Related]
18. FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival.
Gerbaudo VH; Mamede M; Trotman-Dickenson B; Hatabu H; Sugarbaker DJ
Eur J Nucl Med Mol Imaging; 2011 May; 38(5):810-21. PubMed ID: 21210110
[TBL] [Abstract][Full Text] [Related]
19. Talc Pleurodesis With Intense 18F-FDG Activity But No 68Ga-DOTA-TATE Activity on PET/CT.
Papadakis GZ; Millo C; Bagci U; Patronas NJ; Stratakis CA
Clin Nucl Med; 2015 Oct; 40(10):819-20. PubMed ID: 26018715
[TBL] [Abstract][Full Text] [Related]
20. Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment.
Basu S; Saboury B; Torigian DA; Alavi A
Mol Imaging Biol; 2011 Oct; 13(5):801-11. PubMed ID: 21136185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
